Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth

New Biotechnology

Volumn 30, Issue 2, 2013, Pages 205-209

  Behdani, Mahdi ^a   Zeinali, Sirous ^a   Karimipour, Morteza ^a   Khanahmad, Hossein ^a,b   Schoonooghe, Steve ^c,d   Aslemarz, Azam ^a   Seyed, Negar ^a   Moazami Godarzi, Reza ^a   Baniahmad, Farzad ^a   Habibi Anbouhi, Mahdi ^a   Hassanzadeh Ghassabeh, Gholamreza ^c,d   Muyldermans, Serge ^c,d  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS TARGETING; ANIMAL MODEL; ANTIGEN-BINDING; CELL SURFACES; HEAVY-CHAIN ANTIBODIES; IMMUNOTOXINS; IN-VITRO; NEOVASCULARIZATION; PSEUDOMONAS EXOTOXIN A; SINGLE DOMAINS; TUMOR CELLS; TUMOR METASTASIS; TUMOR THERAPY; TUMOR VASCULATURE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR; VEGFR-2;

ANTIBODIES; BACTERIA; BLOOD VESSELS; CELL MEMBRANES; PHYSIOLOGICAL MODELS;

TUMORS;

ANTINEOPLASTIC AGENT; NANOBODY; PSEUDOMONAS EXOTOXIN A; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; CELL PROLIFERATION; CHROMATOGRAPHY, GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOTOXINS; HEK293 CELLS; HUMANS; IMMUNOTOXINS; NEOPLASMS; RECOMBINANT PROTEINS; SINGLE-DOMAIN ANTIBODIES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VIRULENCE FACTORS;

ANIMALIA; CAMELIDAE; PSEUDOMONAS EXOTOXIN;

EID: 84872382607     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2012.09.002     Document Type: Article

References (26)

1. Andersson Y., et al. Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. Br. J. Cancer 2009, 101:1307-1315.
2. Risberg K., et al. Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma. PLoS One 2011, 6:e24012.
3. Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol. Immunother. 2003, 52:338-341.
4. Song S., et al. Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli. Protein Expr. Purif. 2005, 44:52-57.
5. Kreitman R.J. Immunotoxins for targeted cancer therapy. AAPS J. 2006, 8:E532-E551.
6. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
7. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007, 6:273-286.
8. Behdani M., et al. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol. Immunol. 2012, 50:35-41.
9. Backer M.V., Backer J.M. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. Bioconjug. Chem. 2001, 12:1066-1073.
10. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
11. Bikfalvi A. Angiogenesis and invasion in cancer. Handb. Clin. Neurol. 2012, 104:35-43.
12. Fan F., et al. Targeting the tumor microenvironment: focus on angiogenesis. J. Oncol. 2012, 2012:281261.
13. Vermeulen P.B., et al. Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer 2010, 116(11 Suppl.):2748-2754.
14. Tomanek R.J., et al. VEGF family members regulate myocardial tubulogenesis and coronary artery formation in the embryo. Circ. res. 2006, 98:947-953.
15. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005, 94:209-231.
16. Silva S.R., et al. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int. J. Cancer 2011, 128:1045-1056.
17. Molhoek K.R., et al. VEGFR-2 expression in human melanoma: revised assessment. Int. J. Cancer 2011, 129:2807-2815.
18. Lushnikova A.A., et al. VEGFR-2 expression in tumor tissue of breast cancer patients. Dokl. Biol. Sci. 2010, 434:363-367.
19. Backera M.V., et al. Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2. J. Control. Release 2001, 74:349-355.
20. Arora N., et al. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res. 1999, 59:183-188.
21. Hu C., et al. Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model. Int. J. Cancer 2010, 127:2222-2229.
22. Kreitman R.J., et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 2000, 18:1622-1636.
23. Kreitman R.J., et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J. Clin. Oncol. 2009, 27:2983-2990.
24. Pai L.H., et al. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat. Med. 1996, 2:350-353.
25. Garland L., et al. Phase I trial of intravenous IL-4 Pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J. Immunother. 2005, 28:376-381.
26. Parney I.F., et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J. Neurosurg. 2005, 102:267-275.